Biotech Values

[pcrutch]

Wonder what effect NVS will have on them, Ph3 data in second half of this year on PKC412 in FLT3+ AML. Could present a challenge to AMBI trial enrollment and future sales competition.

http://clinicaltrials.gov/ct2/show/NCT00651261?term=Midostaurin&rank=14

Interesting info. Long road ahead for AMBI - NVS had to screen 3200 patients to get 700 randomized.
http://www.iom.edu/~/media/Files/Activity%20Files/Disease/NCPF/2013-FEB-11/Capdeville.pdf